Valvular & structural heart diseaseCohort study

Long-Term Outcomes After Edge-to-Edge Repair of Secondary Mitral Regurgitation

JACC Cardiovasc IntervPublished

  • Registry-based cohort study
  • multicentre
  • real-world registry (EuroSMR)

Authors' conclusion

This extensive multicenter registry underscores the long-term efficacy of M-TEER in real-world clinical practice and identifies predictors for long-term survival.

Study context

Population
Patients with significant secondary mitral regurgitation (MR) undergoing M-TEER (mean age 73.8 years, mean EuroSCORE II 6.9%, 86.6% NYHA class ≥III)
Participants
1,628 patients
Outcome
Long-term MR reduction, functional outcomes, survival and predictors of all-cause mortality
Follow-up
5 years

Main finding

As reported in the abstract

Five-year survival after M-TEER

Five-year survival

35.0%

Observational data: associations, not effects.

Further findings

5-year survival by residual MR grade

Residual MR ≤1+
38.6%
Residual MR 2+
30.5%
Residual MR ≥3+
22.6%
  • P < 0.001

Independent predictors of 5-year all-cause mortality

Age, renal function, residual MR, NYHA class, LVEF and COAPT trial eligibility
P < 0.01 for all

Original publication

Long-Term Outcomes After Edge-to-Edge Repair of Secondary Mitral Regurgitation. JACC Cardiovasc Interv. Published 11 November 2024. doi:10.1016/j.jcin.2024.08.016

Summarised from the published abstract; every number is checked against it